Seoul, 100-715
Korea, Republic of (South Korea)
hepatocellular carcinoma, liver cancer, nivolumab, PD-1 inhibitor, sorafenib, immuno-oncology, CheckMate
landmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint